BCM
ASBPW

Basso Capital Management’s Aspire Biopharma Warrant ASBPW Stock Holding History

Basso Capital Management’s Portfolio ASBPW Stock Details ASBPW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-50,400
Closed -$6K – 118
2022
Q3 		$6K Buy
+50,400
New +$7.34K ﹤0.01% 311

Other funds holding ASBPW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AC
Athos Capital Hong Kong $324M AUM 16.62% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Basso Capital Management's ASBPW Position: Q4 2022 in Review

Basso Capital Management sold out of Aspire Biopharma Warrant (ASBPW) in Q4 2022, closing a stake of 50,400 shares — an estimated $6K sold.

Basso Capital Management first reported a position in ASBPW in Q3 2022 and held it in 1 quarter. The position peaked at $6K in Q3 2022. 36 funds tracked by Wall St. Rank hold ASBPW as of Q4 2022.

  • Basso Capital Management reported no remaining Aspire Biopharma Warrant position as of Q4 2022 after selling out during the quarter.
  • Basso Capital Management sold 50,400 Aspire Biopharma Warrant shares in Q4 2022, an estimated $6K.
  • Basso Capital Management first reported a position in Aspire Biopharma Warrant in Q3 2022 and held it in 1 quarter.
  • Basso Capital Management's Aspire Biopharma Warrant position peaked at $6K in Q3 2022.
  • 36 funds tracked by Wall St. Rank held Aspire Biopharma Warrant as of Q4 2022.

Based on Basso Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.